In clinical samples, several studies have found an overexpression of CD133 in GC tissue with respect to the non-neoplastic gastric mucosa, as well as an association of this marker with adverse clinicopathological parameters such as tumor size, lymphatic/vascular infiltration, TNM stage, depth of invasion, distant metastasis and reduced survival [94,98,116,117,118,119]. This evidence concerns the gene PROM1 and neoplasm.